These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 10218526)

  • 21. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
    Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H;
    J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
    Mussini C; Pezzotti P; Antinori A; Borghi V; Monforte Ad; Govoni A; De Luca A; Ammassari A; Mongiardo N; Cerri MC; Bedini A; Beltrami C; Ursitti MA; Bini T; Cossarizza A; Esposito R;
    Clin Infect Dis; 2003 Mar; 36(5):645-51. PubMed ID: 12594647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of pneumocystis pneumonia after cessation of secondary prophylaxis.
    Quah SP; McBride M
    Int J STD AIDS; 2001 Feb; 12(2):126-7. PubMed ID: 11236102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stopping PCP prophylaxis after suppressing HIV.
    Norton M
    GMHC Treat Issues; 1999 Apr; 13(4):4-5. PubMed ID: 11366976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group.
    Lundgren JD; Phillips AN; Vella S; Katlama C; Ledergerber B; Johnson AM; Reiss P; Gatell J; Clumeck N; Dietrich M; Benfield TL; Nielsen JO; Pedersen C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):153-60. PubMed ID: 9390566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
    Lim PL; Zhou J; Ditangco RA; Law MG; Sirisanthana T; Kumarasamy N; Chen YM; Phanuphak P; Lee CK; Saphonn V; Oka S; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Li PC; Merati TP; Yunihastuti E; Messerschmidt L; Sungkanuparph S;
    J Int AIDS Soc; 2012 Jan; 15(1):1. PubMed ID: 22281054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumocystis jirovecii prophylaxis discontinuation based upon total lymphocyte count in HIV-infected adults treated with antiretroviral therapy.
    Cheung C; Shuter J
    Int J STD AIDS; 2010 Jun; 21(6):406-9. PubMed ID: 20606220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study.
    Zellweger C; Opravil M; Bernasconi E; Cavassini M; Bucher HC; Schiffer V; Wagels T; Flepp M; Rickenbach M; Furrer H;
    AIDS; 2004 Oct; 18(15):2047-53. PubMed ID: 15577626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
    Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
    Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
    Sidhu VK; Foisy MM; Hughes CA
    Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Occurrence of Pneumocystis carinii pneumonia in HIV-1-infected patients responding to HAART: is prophylaxis discontinuation a safe tool?
    Mezzaroma I; Giovannetti A; Pinter E; Ensoli F; Aiuti F
    AIDS; 1999 Dec; 13(17):2488-9. PubMed ID: 10597798
    [No Abstract]   [Full Text] [Related]  

  • 33. Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF).
    Stoehr A; Arasteh K; Staszewski S; Brockmeyer N; Albrecht H; Mertenskötter T; Jablonowski H; Emminger C; Rockstroh JK; Baumgarten R; Bogner J; Loch T; Plettenberg A
    Eur J Med Res; 1999 Apr; 4(4):131-4. PubMed ID: 10205287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
    Kirk O; Lundgren JD; Pedersen C; Nielsen H; Gerstoft J
    AIDS; 1999 Sep; 13(13):1647-51. PubMed ID: 10509565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group.
    Stansell JD; Osmond DH; Charlebois E; LaVange L; Wallace JM; Alexander BV; Glassroth J; Kvale PA; Rosen MJ; Reichman LB; Turner JR; Hopewell PC
    Am J Respir Crit Care Med; 1997 Jan; 155(1):60-6. PubMed ID: 9001290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumocystis pneumonia among HIV patients in Malaysia.
    Asmal HS; Mustafa M; Abdullah S; Zaidah AR; Nurhaslindawati AR; Sarimah A; Chan YY; Ravichandran M
    Southeast Asian J Trop Med Public Health; 2009 Nov; 40(6):1293-7. PubMed ID: 20578464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
    Green H; Hay P; Dunn DT; McCormack S;
    HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis.
    Trikalinos TA; Ioannidis JP
    Clin Infect Dis; 2001 Dec; 33(11):1901-9. PubMed ID: 11692302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial.
    Qin Y; Lu Y; Zhou Y; Harypursat V; Sun F; Yang S; Tang S; Li Y; He X; Zeng Y; Chen Y
    Trials; 2020 Jun; 21(1):551. PubMed ID: 32571429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.